- Seelos Therapeutics Inc (NASDAQ:SEEL) temporarily pauses additional enrollment of patients in the SLS-005-302 study in spinocerebellar ataxia type 3 (SCA3).
- Patients already enrolled will continue in the study, and data will continue to be collected to make decisions for resuming enrollment.
- This temporary pause has been implemented as a business decision due to financial considerations and is not based on any data related to safety or therapeutic effects.
- The company will focus most of its resources on the ongoing study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and the fully enrolled phase 2/3 study of SLS-005 in amyotrophic lateral sclerosis (ALS).
- The company is targeting data readout from the SLS-002 study in the third quarter of 2023, and data readout from the SLS-005 study in ALS is expected in late 2023.
- Seelos said it is awaiting the final results of non-clinical toxicology required to initiate dosing in the SLS-003 program in complex regional pain syndrome and putting any non-essential preclinical work on hold.
- Price Action: SEEL shares closed at $0.72 on Wednesday.
RBC Capital Markets Initiates Coverage On This ‘Well Positioned’ Pet Company
RBC Capital Markets initiated Petco Health and Wellness Company Inc (NASDAQ: WOOF) with an Outperform rating and a $17 price target.
